Bio/Pharma News

Roche Forms Partnership Worth Potentially More than $1 Billion with Innovent to Develop Novel ADC for SCLC

January 03, 2025

Under the agreement, the companies will advance development of IBI3009, Innovent’s ADC candidate, which has received IND approvals in the US, China, and Australia.

First Generic of a GLP-1 Injection Gets FDA Nod to Treat Type 2 Diabetes

December 27, 2024

FDA's approval of Hikma Pharmaceuticals’ liraglutide injection makes this product the first generic version of Victoza, a GLP-1 receptor agonist.

Prasinezumab Misses Primary Endpoint in Roche’s Phase IIb Study, but Has Potential in Treating Early Stage Parkinson’s Disease

December 25, 2024

Results from a Phase IIb study missed the primary endpoint by failing to achieve statistical significance.

Orexo and Abera Partner to Develop Nasal Powder Vaccines

December 20, 2024

The companies will use Orexo’s powder-based drug delivery technology to develop mucosal vaccines in an inhaled formulation.

AbbVie to Boost Immunology Pipeline with Acquisition of Nimble Therapeutics

December 18, 2024

AbbVie's latest acquisition target is Nimble Therapeutics, which will give AbbVie a lead asset, an oral peptide for treating psoriasis.

GSK Enters into Strategic Collaborations with Relation and Muna to Advance Drug Development

December 12, 2024

With these agreements, the respective parties will work to advance therapeutic candidates for treating fibrotic diseases, osteoarthritis, and Alzheimer’s disease.

BioMarin to Increase Production Capacity with €60 Million Expansion at Ireland Facility

December 12, 2024

With this investment, BioMarin will add a new laboratory to its Shanbally, Co. Cork, Ireland, manufacturing facility.

AbbVie Acquires Aliada Therapeutics, Gains Neuroscience Pipeline

December 11, 2024

AbbVie has completed its acquisition of Aliada Therapeutics which includes Aliada’s disease-modifying therapy for Alzheimer’s disease.

Novartis Enters $2.9 Billion License Agreement with PTC Therapeutics for Huntington’s Disease Development Program

December 10, 2024

Novartis will in-license PTC's PTC518 program, which has the potential become the first oral disease-modifying therapy for Huntington's disease.

Lilly and Amgen Each Announce Major Expansions of US Manufacturing Sites

December 06, 2024

Lilly is investing $3 billion to expand its recently acquired manufacturing facility in Wisconsin, while Amgen is investing $1 billion to expand its facility in North Carolina.